Cancer drug cabozantinib tested in tough prostate cancers
NCT ID NCT04631744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug cabozantinib in men with a hard-to-treat type of prostate cancer that had spread and stopped responding to hormone therapy. The study focused on patients whose tumors had specific genetic changes or had spread to the liver. Only 4 men were enrolled before the trial was stopped early, so the results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib
What this could lead to
If it works, this could point toward a treatment option for men with advanced prostate cancer that has specific genetic changes or spread to the liver.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States